Expert consensus on immune checkpoint inhibitors for non-small cell lung cancer
International Open Medical Journal (IOMJ) · 09.11.2026 · 2 · 103-168
DOI: 10.65364/iomj.2026.07 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Open Medical Journal (IOMJ), online erschienen am 09.11.2026. Verfasst von Danru Zheng und 39 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, characterized by high morbidity and mortality. Traditional treatments, including surgery, chemotherapy, and radiotherapy, have long been the mainstay of management. However, the advent of targeted therapy and immunotherapy, particularly immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 antibodies, has significantly improved patient survival outcomes. These advancements have transformed the therapeutic landscape for early-stage, locally advanced, and advanced NSCLC without actionable gene mutations. Despite multiple ICIs being approved for clinical use, critical questions regarding the optimal beneficiary population and predictive biomarkers remain under investigation. To address these challenges, the Yangtze River Delta Lung Cancer Cooperation Group (ECLUNG; Youth Committee) has formulated an expert consensus on the diagnosis and treatment of NSCLC with ICIs. This consensus aims to provide standardized and evidence-based recommendations to optimize diagnostic precision and therapeutic decision-making in NSCLC.
Zitieren
APA
Zheng, D., Xu, C., Wang, Q., Wang, W., Wang, D., Lan, F., Yu, J., Zhong, W., Wang, Z., Fang, W., Zhang, Y., Liu, J., Zhang, S., Zhang, Y., Liu, A., Liu, W., Zhan, P., Liu, H., Lv, T., …, & Chen, X. (2026). Expert consensus on immune checkpoint inhibitors for non-small cell lung cancer. International Open Medical Journal (IOMJ), 2, 103-168. https://doi.org/10.65364/iomj.2026.07
Vancouver
Zheng D, Xu C, Wang Q, Wang W, Wang D, Lan F, et al. Expert consensus on immune checkpoint inhibitors for non-small cell lung cancer. International Open Medical Journal (IOMJ). 2026;2:103-168. doi:10.65364/iomj.2026.07
BibTeX
@article{Zheng2026,
author = {Zheng, Danru and Xu, Chunwei and Wang, Qian and Wang, Wenxian and Wang, Dong and Lan, Fangcen and Yu, Jinpu and Zhong, Wenzhao and Wang, Zhijie and Fang, Wenfeng and Zhang, Yongchang and Liu, Jingjing and Zhang, Shirong and Zhang, Yu and Liu, Anwen and Liu, Wen and Zhan, Ping and Liu, Hongbing and Lv, Tangfeng and Miao, Liyun and Min, Lingfeng and Lin, Gen and Yuan, Jingping and Jiang, Zhansheng and Huang, Long and Pu, Xingxiang and Rao, Chuangzhou and Lv, Dongqing and Yu, Zongyang and Li, Xiaoyan and Tang, Chuanhao and Zhou, Chengzhi and Zhang, Junping and Guo, Hui and Chu, Qian and Meng, Rui and Wu, Jingxun and Zhou, Jin and Zhu, Zhengfei and Chen, Xiaofeng},
title = {Expert consensus on immune checkpoint inhibitors for non-small cell lung cancer},
journal = {International Open Medical Journal (IOMJ)},
year = {2026},
volume = {2},
pages = {103--168},
doi = {10.65364/iomj.2026.07}
}
EUVIMED